Abstract: The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

Abstract: The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

Abstract: The disclosure relates to reduced signaling to carry out the linking between new radio (NR) carrier aggregation (CA) band combinations and NR band processing combinations (BPCs), and includes apparatus and methods of receiving, at a modem of a user equipment (UE), a UE configuration from a base station based on UE band combination constraint information, configuring the UE, by a processor of the UE, according to the UE configuration, and performing a communication with the base station, via the modem of the UE, according to the UE configuration. In an implementation, the disclosure includes transmitting the UE band combination constraint information, such as in the form of receiving a total number of layers supported in a CA band combination, and wherein receiving the UE configuration further comprises receiving a CA combination and a BPC configuration in response to the UE band combination constraint information.

Abstract: The disclosure relates to reduced signaling to carry out the linking between new radio (NR) carrier aggregation (CA) band combinations and NR band processing combinations (BPCs), and includes apparatus and methods of receiving, at a modem of a user equipment (UE), a UE configuration from a base station based on UE band combination constraint information, configuring the UE, by a processor of the UE, according to the UE configuration, and performing a communication with the base station, via the modem of the UE, according to the UE configuration. In an implementation, the disclosure includes transmitting the UE band combination constraint information, such as in the form of receiving a total number of layers supported in a CA band combination, and wherein receiving the UE configuration further comprises receiving a CA combination and a BPC configuration in response to the UE band combination constraint information.

Abstract: The present invention relates to 4-substituted amidine derivatives of the general formula (I), wherein A1-A4, D, L, Q, R7, R7? and integer's v and w have the meanings as defined in description. The invention further relates to methods for their preparation and use of said compounds to fight undesired phytopathogenic microorganisms, and agents for said purpose, comprising said amidine derivatives, all according to the invention. This invention further relates to a method for controlling undesired phytopathogenic microorganisms by application of said 4-substituted amidine derivatives of general formula (I) to such undesired microorganisms and/or to their habitat, according to the invention.

Abstract: Certain aspects of the present disclosure relate to methods and apparatus for maintaining phase coherency in the event of changes to uplink transmit power. For example, the techniques described herein may help mitigate the impact on phase continuity of uplink transmissions by UEs capable of dual connectivity (DC).

Abstract: The disclosure relates to reduced signaling to carry out the linking between new radio (NR) carrier aggregation (CA) band combinations and NR band processing combinations (BPCs), and includes apparatus and methods of receiving, at a modem of a user equipment (UE), a UE configuration from a base station based on UE band combination constraint information, configuring the UE, by a processor of the UE, according to the UE configuration, and performing a communication with the base station, via the modem of the UE, according to the UE configuration. In an implementation, the disclosure includes transmitting the UE band combination constraint information, such as in the form of receiving a total number of layers supported in a CA band combination, and wherein receiving the UE configuration further comprises receiving a CA combination and a BPC configuration in response to the UE band combination constraint information.

Abstract: The present invention relates to fused heterocyclic compound of Formula (I), a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

Abstract: Certain aspects of the present disclosure relate to methods and apparatus for wireless communication. In certain aspects, the method generally includes determine a transmission power for each of at least one first sounding reference signal (SRS) to be transmitted using at least one first antenna, wherein the determination is based on whether the at least one first SRS is transmitted using an amplifier of a transmit chain configured for transmissions using a second antenna, and transmitting the at least one first SRS based on the determination.

Abstract: The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

Abstract: The present invention relates to fused heterocyclic compound of Formula (I), a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.